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Abstract
Objectives
Our aim was to prospectively determine whether quantitative computed tomography (CT)
scores, consisting of simplified indices for liver remodeling and attenuation, may predict liver
fibrosis in abdominal CT scans.
Materials and methods
This cross-sectional, prospective study was approved by the local IRB (Kantonale Ethik-
kommission Bern). Written informed consent was given from all patients undergoing study-
MR exams. Between 02/16 and 05/17, four different liver fibrosis scores (CRL-R = caudate-
right-lobe ratio, LIMV-, LIMA- and LIMVA-fibrosis score, with “LIM” for liver imaging morphol-
ogy, “V” for liver vein diameter and “A” for attenuation) were calculated in 1534 consecutive
abdominal CT scans, excluding patients with prior liver surgery and liver metastasis.
Patients were invited to undergo magnetic resonance (MR) elastography as the non-inva-
sive gold standard to evaluate liver fibrosis. MR elastography shear modulus2.8 kPa was
defined as beginning liver fibrosis, while3.5 kPa was defined as significant liver fibrosis
(which would correspond to fibrosis stage F2 or higher in histology). Cutoff values, sensitivi-
ties and specificities obtained from the receiver operating characteristics (ROC) analysis
were then calculated in 141 patients who followed the invitation for MR elastography. To mit-
igate selection bias, prevalence was estimated in the screened total population (n = 1534)
by applying the cutoff values with sensitivities and specificities calculated in the MR elasto-
graphy sub-group. Positive predictive values (PPV) and negative predictive values (NPV)
were then calculated.
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Results
Fibrosis scores including liver vein attenuation LIMA-FS and LIMVA-FS showed higher
areas under the ROC curves (0.96–0.97) than CRL-R (0.82) to detect significant liver fibro-
sis, while LIMV-FS showed good performance as well (0.92). The prevalence-corrected
PPV were 29% for CRL-R, 70% for LIMV-FS, 76% for LIMA-FS and 82% for LIMVA-FS.
Conclusion
CT fibrosis scores, notably LIMA-FS and LIMVA-FS, may predict significant liver fibrosis on
routine abdominal CT scans.
Introduction
With demographic trends toward an aging population [1] and with an increasing prevalence
of obesity and metabolic syndrome [2], chronic liver disease has become an important health-
care issue [3,4]. Nevertheless, chronic liver disease, and consequent liver fibrosis, remains
under recognized [5], leading to significant morbidity and mortality [6]. Indeed, due to its
reversibility during treatment [7,8], early diagnosis might decrease the disease burden, prevent
hepatocellular carcinoma (HCC) [9] and lower healthcare costs [10].
Several non-invasive imaging methods, especially ultrasound and magnetic resonance
(MR) elastography, enable non-invasive detection of liver fibrosis [11]. However, to date no
systematic screening program for the general population exists to detect liver fibrosis in clini-
cally occult stages. Cross-sectional studies have shown a significant elevation in liver stiffness
(shear modulus8 kPa in FibroScan1 assessments, which would correspond to fibrosis
grade F2 or higher in histology) in 7.5% of the general population [12], while the prevalence of
non-alcoholic fatty liver disease, is now estimated to be as high as 27–42% [13–15]. Current
CT methods for detecting liver fibrosis are reader-dependent [16], or they rely on time-con-
suming image post-processing methods such as liver segmental volumetry [17], CT texture
analysis [18] or the liver surface nodularity score [19]. However, quantitative, reproducible
metrics to assess liver fibrosis on abdominal CT scans without image post-processing, such as
the caudate-right-lobe ratio (CRL-R) [20] and the liver imaging morphology and vein diame-
ter fibrosis score (LIMV-FS) [21], have shown good accuracies to differentiate cirrhotic livers
from normal livers with areas under the receiver operating characteristics (ROC) curve of
0.79–0.89. We hypothesized that an extension of these morphology-based fibrosis scores, via a
simple comparison of the liver vein attenuation to the inferior vena cava attenuation in the
portal venous phase as an indirect and simplified surrogate for liver perfusion (LIMA-FS: liver
imaging morphology and attenuation fibrosis score and LIMVA-FS: liver imaging morphol-
ogy, vein diameter and attenuation fibrosis score), would additionally increase the perfor-
mance of these scores.
The aim of this study was to prospectively determine whether such quantitative computed
tomography (CT) scores may predict liver fibrosis in abdominal CT scans.
Materials and methods
Study population
This prospective cross-sectional study was approved by the institutional review board (IRB
number 282–15) and conducted after obtaining written patient informed consent. Patients
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<18 years, patients >70 years and patients with liver masses, portal vein thrombosis, prior
liver surgery and contraindications for MR imaging were excluded. A total of 1534 consecutive
portal venous phase abdominal CT scans from 1474 patients (52 patients underwent1 CT
scan) in our institution were analyzed between 02/2016-05/2017. All these patients were
invited for MR elastography as non-invasive reference standard to diagnose liver fibrosis. 148
patients (10%) accepted our invitation without financial compensation. Time interval between
CT and MR scans was 116±36 days in average. 7 patients had to be excluded because of techni-
cally inadequate MR elastography due to susceptibility artifacts or early cessation of the MR
exam due to claustrophobia, resulting in an MR elastography study population of 141 patients
(Fig 1). Additionally, 20 consecutive patients with abdominal CT scans and known biopsy-
confirmed liver cirrhosis (Metavir F4) were included. To avoid selection bias, these patients
were just used as positive controls with 95% confidence intervals but not included in the statis-
tical analysis to determine PPV and NPV of the analyzed fibrosis scores. Clinical information
and laboratory test results were recorded.
CT imaging and post-processing
CT scans were acquired on Siemens Somatom Definition Flash, Definition Edge (Siemens
Healthineers, Erlangen, Germany) and Philips Brilliance 64 (Philips, Best, Netherlands) scan-
ners with a pitch of 0.8 and a detector collimation of 0.6. The acquisitions were performed
with attenuation based KV selection and automated mAs adaption using references of 100
kVp and 150 mAs. Axial 1-mm slices were reconstructed with an increment of 1 mm in a liver
parenchyma window, using the vendor-specific iterative reconstruction algorithm.
Liver remodeling is associated with the following CT morphological changes: 1) atrophy of
the right liver lobe and hypertrophy of the caudate and left liver lobe, increasing the CRL-R
[20]; 2) compression of the liver veins resulting in a decrease in the liver vein diameter (LVD)
[21,22]; and 3) decreased hepatic microperfusion [23,24]. While CRL-R and LVD are represent
morphologic parameters as already shown in other studies [20–22,25], we introduced the liver
vein to cava attenuation (LVCA) as a simplified surrogate for perfusion. The idea was that
mean transit time of IV contrast agent through the liver will be delayed due to altered hepatic
perfusion in liver fibrosis [26,27], while the systemic venous blood return will be stable. We
hypothesized that the newly introduced liver vein to cava attenuation (LVCA) on portal
venous phase would allow a simple comparison of hepatic perfusion time (the time until the
contrast has reached the hepatic veins) to the systemic, extrahepatic venous blood return (the
time until the contrast has reached the inferior vena cava). In normal liver parenchyma, the
applied contrast medium reaches the liver veins earlier than the inferior vena cava. Therefore,
a visual categorical grading system depending on the liver vein attenuation compared to atten-
uation of the inferior vena cava (IVC) was used: 1 hyper-attenuating, 2 iso-attenuating, 3
hypo-attenuation, while a score of 4 was given if liver veins were not visibly contrasted. IVC
attenuation was assessed 1 cm inferior to the liver vein confluence and liver vein attenuation
was assessed 1 cm proximal to the liver vein confluence. In visually similar attenuation
between IVC and liver veins, a region of interest was drawn in the IVC and the largest of
the three liver veins, while a difference of less than 20 Hounsfield Units was rated as iso-
attenuating.
All 1534 consecutive CT scans were analyzed using four different fibrosis scores (CRL-R,
LIMA-, LIMV- and LIMVA-FS) as follows:
CRL   R ¼
CLD
RLD
CT predicts liver fibrosis
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LIMV   FS ¼
LVD
CRL   R
LIMA   FS ¼ CLR   R LVCA
LIMVA   FS ¼
LVD
CLR   R x LVCA
where CLD = caudate lobe diameter, RLD = right lobe diameter, LVD = liver vein diameter,
LVCA = liver vein to cava attenuation.
The medial margin of the caudate lobe and lateral margin of the right liver lobe were identi-
fied by scrolling through the slices. The axial section presenting the first right portal vein bifur-
cation was then selected and the distance to the medial and lateral margin of the right liver
(projected on this slice) was measured strictly horizontally from there (Fig 2). These measure-
ments constitute the caudate lobe diameter (CLD) and the right lobe diameter (RLD) used to
calculate the CRL-R, as described before [20]. Portal vein anatomy variants were considered as
indicated in Fig 3. Liver vein diameter (LVD) was defined as the sum of the three main hepatic
vein diameters 1 cm proximal to the aperture into the IVC (Fig 2). Images were evaluated by
two radiologists with 3 (N.M.) and 5 (V.O.) years of experience in liver imaging on a dedicated
reading workstation with a 5MP display (MDCC-6230, Barco, Kortrijk, Belgium) using Picture
Archiving and Communication System (PACS) (IDS7, SECTRA, Linko¨ping, Sweden). In
unclear cases, the readers consulted each other’s opinion and then decided in consensus.
Fig 1. Study workflow chart. CT Fibrosis scores (CRL-R, LIMA-, LIMV- and LIMVA-FS) were calculated on 1534 consecutive CT scans. All patients
received invitations for MR elastography, resulting in a subpopulation of 148 following the MR invitation. Optimal cutoffs to predict significant liver
fibrosis (3.5 kPa in MR elastography) were determined with ROC analysis. These cutoffs with corresponding sensitivities and specificities were then
applied to the whole population for prevalence estimation, allowing for calculations of the PPV and NPV of CRL-R, LIMA-, LIMV- and LIMVA-FS to
predict significant liver remodeling. CRL-R = caudate-right-lobe ratio, LIMA-FS = liver imaging morphology and attenuation fibrosis score,
LIMV-FS = liver imaging morphology and vein diameter fibrosis score, LIMVA-FS = liver imaging morphology, vein diameter and attenuation fibrosis
score, CT = computed tomography, MR elastography = magnetic resonance elastography, ROC = Receiver operating characteristics, PPV = positive
predictive value, NPV = negative predictive value.
https://doi.org/10.1371/journal.pone.0199611.g001
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MR imaging technique and imaging analysis
Patients were examined with a 3T-MR system (Verio, Siemens Healthineers, Erlangen, Ger-
many) in a fasting state (>6 h). A pneumatic driver (Resoundant, Rochester, MN, USA) was
placed on the right upper quadrant transmitting shear waves by continuous acoustic vibrations
at 60 Hz. The liver shear modulus in kPa in the right upper liver lobe was determined with a
gradient echo-based elastography sequence (WIP package 622 provided by Siemens Healthi-
neers, 3 single-slice acquisitions with 5-mm slice thicknesses) using the 95% confidence map
of stiffness. The MR elastography reading radiologist (A.H.), with 7 years of experience in liver
imaging, was blinded to the results of the CT scans. Patients with MR elastography results
Fig 2. Liver imaging morphology and attenuation fibrosis score (LIMA-FS) and liver imaging morphology, vein
diameter and attenuation fibrosis score (LIMVA-FS) in two patients. Images A & C show axial mid-liver slices on
the level of the portal vein. The distances of the right lateral border of the right portal vein bifurcation to the lateral
margin of the right hepatic lobe (RLD) and to the most medial margin of the caudate lobe (CLD) are measured in an
exactly horizontal direction. The two distances were divided CLD/RLD and defined as the caudate-right-lobe ratio
(CRL-R). Images B & D show the proximal liver veins and inferior vena cava (IVC). The diameter of each vein is
measured, and the sum results in the liver vein diameter (LVD). The liver vein density () is compared visually to the
ICV density (#), and the liver vein to cava attenuation (LVCA) is assessed. Images A & B are from a 46-year-old female
patient without liver remodeling (shear modulus 2.0 kPa) and with LIMA-FS = 1.02 and LIMVA-FS = 26.5. Images C
& D are from a 47-year-old male patient with significant liver remodeling (MRE = 4.1 kPa) without steatosis
(PDFF = 5.8%). Note that in this patient, the liver veins are not contrasted (LVCA = 4) LIMA-FS = 4.88,
LIMVA-FS = 2.46. RLD = right lobe diameter, CLD = caudate lobe diameter, LVD = liver vein diameter,
IVC = inferior vena cava, LCVD = liver vein to cava density; LIMA-FS = liver imaging morphology and attenuation
fibrosis score; LIMVA-FS = liver imaging morphology, vein diameter and attenuation fibrosis score, PDFF = proton
density fat fraction.
https://doi.org/10.1371/journal.pone.0199611.g002
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3.5 kPa were referred to our hepatology department for clinical anamnesis, laboratory tests
and FibroScan1 assessments. The cutoff value of 3.5 kPa was chosen corresponding to the
8-kPa cutoff in FibroScan1, since it corresponds to a fibrosis stageF2 in histology, generally
regarded as significant fibrosis [28–30]. A lower shear modulus cutoff2.8 kPa was consid-
ered as beginning liver remodeling (fibrosis stageF1) [31,32]. The Dixon method with axial
T1-weighted axial vibe images (TE of 2.45 ms, TR of 5.47 ms, 3-mm slice thickness) was used
to calculate the proton density fat fraction to differentiate patients with and without liver
steatosis.
Statistical analysis
Analysis was performed with the statistical software package R version 3.4.1 [33] and Graph-
Pad Prism (Version 7.1, GraphPad Software Inc, CA, USA). Liver shear modulus in kPa wrer
compared between different LVCA scores (1–4) using the Mann-Whitney-U test. Pearson cor-
relation was calculated between MR Elastography and LVCA and used to compare CT fibrosis
Fig 3. Caudate-right-lobe ratio in case of portal venous variants. In normal anatomy, the first bifurcation of the right portal vein (RPV) is used for the caudate-
right-lobe ratio (CRL-R) calculation A), while anatomic variants are shown on the right side of the figure. B-E) In cases of an anomalous origin of the left portal
vein (LPV), the first bifurcation of the RPV is used as in the normal variant, illustrated in B) and D). In the case of an early origin of the right posterior branch,
the first bifurcation of the right anterior branch is measured C). In the case of an origin of the right anterior branch from the LPV, the first bifurcation of the right
posterior branch is measured E). RPV = right portal vein; CRL-R = caudate-right-lobe-ratio; LPV = left portal vein.
https://doi.org/10.1371/journal.pone.0199611.g003
CT predicts liver fibrosis
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scores with liver shear modulus in kPa. The different CT fibrosis scores and clinical parameters
were compared between patients with normal and elevated shear modulus2.8 kPa, as well as
between patients with beginning (shear modulus 2.8–3.5 kPa) and significant liver fibrosis
(shear modulus3.5 kPa) using the Mann-Whitney-U test for continuous variables and Fish-
er’s exact test for categorical variables. Optimal cutoff values of the CT fibrosis scores were cal-
culated with the ROC analysis to predict beginning (2.8 kPa) and significant (3.5 kPa) liver
fibrosis. Area under the curves (AUC) with 95%-confidence intervals were calculated. Cutoff
values were chosen based on Youden’s index. To directly evaluate the performance of different
fibrosis scores, we performed a McNemar test to compare CRL-R with the other three fibrosis
(LIMV-, LIMA- and LIMVA-FS) to predict significant fibrosis by combining pairs of true (t)
and false (f) test results (tt/tf/ft/ff).
To mitigate selection bias, prevalence was estimated in the screened total population
(n = 1534) by applying the cutoff values with sensitivities and specificities calculated in the MR
elastography sub-group. Positive predictive values (PPV) and negative predictive values (NPV)
were then calculated.
For interrater reliability, two blinded radiologists with 5 (V.O.) and 7 (A.H.) years of experi-
ence in liver imaging each calculated the CT fibrosis scores in all MR elastography patients
(n = 141). Two-way consistency intraclass correlation (ICC) was then calculated and classified
as follows: ICC 0.4–0.59 as fair, 0.6–0.74 as good and 0.75–1.00 as excellent [34]. In case of dis-
agreement a consensus reading was performed.
Results
Patient characteristics
Patient characteristics of the MR elastography population are shown in Table 1. Patients with
elevated liver stiffness indicating liver fibrosis were older (mean age 59±13 vs. 52±13 years,
p = 0.012) with a higher proportion of male patients (81% vs. 48%, p = 0.001) than those with
normal liver stiffness. Between the patients with beginning and significant liver fibrosis, no sig-
nificant differences in age were evident (59±13 vs. 58±10 years, p = 0.490). Patients with liver
fibrosis had significantly higher levels of liver enzymes (AST 43±26 vs. 25±12, p<0.001, ALT
43±33 vs. 31±37, p = 0.006, GGT 100±124 vs. 31±31, p<0.001) and bilirubin (19±17 vs. 9.2±6,
p = 0.003) than patients with normal liver stiffness. The Quick value was reduced (81±20 vs. 98
±4, p<0.001), especially in patients with significant liver remodeling (75±20).
As shown in Table 2, all CT fibrosis scores except CRL-R allowed to significantly differenti-
ate between patients with normal liver stiffness and fibrosis, as well as between patients with
beginning and significant liver fibrosis (p<0.001). Hepatic proton density fat fraction, post-
viral hepatitis status, chronic viral hepatitis and alcohol units per day were significantly
increased in patients with fibrosis compared with patients with normal liver stiffness (p =
0.009, <0.001, 0.001 and<0.001, respectively), while the aspartate-aminotransferase-to-plate-
let ratio index, chronic hepatitis and alcohol units per day allowed discrimination of patients
with beginning and significant liver remodeling (p = 0.006, 0.008 and 0.007, respectively).
LVCA correlated well with liver enzymes (AST) as well as fibrosis grade as measured by MRE
(r = 0.73, p<0.001, Fig 4).
ROC analysis
In the ROC analysis, all measured fibrosis scores revealed similar performances toward differ-
entiating patients with any degree of liver fibrosis from those without fibrosis (AUC 0.78–
0.84), as shown in Fig 5. In contrast, attenuation-enhanced LIMA-FS (AUC 0.96, 95%-CI
0.91–1.00) and LIMVA-FS (AUC 0.97, 95%-CI 0.93–1.00) enabled a much better prediction of
CT predicts liver fibrosis
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significant liver fibrosis (corresponding to fibrosis grade F2 or higher) than CRL-R (AUC 0.82,
95%-CI 0.70–0.94), while LIMV-FS showed good performance as well (AUC 0.94, 95%-CI
0.88–0.99). McNemar test showed that CRL-R is significantly inferiority to predict significant
liver fibrosis compared to LIMV-FS, LIMA-FS and LIMVA-FS (p = 0.0013, p = 0.0002 and
p = 0.0002, respectively). In contrary, LIMV-FS was not significantly inferior to LIMA-FS and
LIMVA-FS (p = 0.4497 and p = 0.2278).
Optimal cutoff values with sensitivities, specificities and accuracies are shown in Table 3.
The highest PPV to predict significant liver fibrosis of 82% (74–91%) was achieved with a
LIMVA-FS cutoff value6.7, while the second best parameter, LIMA-FS, achieved a PPV
of 76% (67–96%) with a cutoff value2.85. To rule out significant liver fibrosis, NPV was
98% for both LIMA-FS<2.85 and LIMVA-FS>6.7 but increased to nearly 100% using more
conservative cutoff values (LIMA-FS <1.96 and LIMVA-FS<11.7). Extrapolation of the ROC
results of the MR elastography study population to 1534 consecutive CT scans is shown in
Table 4.
Pearson correlation
When the patients were not separated into categorical subgroups, an increase in liver stiffness
correlated best with an increase in 1/LIMVA-FS (r = 0.76, p<0.001), as shown in Fig 6, fol-
lowed by LIMA-FS (r = 0.71, p<0.001) and 1/LIMV-FS (r = 0.64, p<0.001), while CRL-R
(r = 0.38, p<0.001) showed an inferior performance.
Table 1. Patient characteristics of the MR elastography study population.
Normal liver
stiffness (n = 105)
Any degree of liver fibrosis (shear
modulus 2.8 kPa)(n = 36)
p—
value
Beginning liver fibrosis(shear
modulus 2.8–3.5 kPa)(n = 17)
Significant liver fibrosis(shear
modulus  3.5 kPa)(n = 19)
p—
value
Age, years 52 ± 13 59 ± 13 0.012 59 ± 15 58 ± 10 0.490
Male, % 50 (48%) 29 (81%) 0.001 13 (76%) 16 (84%) 0.684
BMI, kg/m2 27 ± 9 29 ± 7 0.012 29 ± 7 29 ± 7 0.775
Tobacco 16 (15%) 15 (42%) 0.002 4 (24%) 11 (58%) 0.049
Arterial
hypertension
22 (21%) 13 (36%) 0.078 4 (24%) 9 (47%) 0.177
Dyslipidemia 8 (11%) 8 (26%) 0.082 5 (29%) 3 (16%) 0.434
Diabetes 5 (5%) 10 (28%) <0.001 3 (18%) 7 (37%) 0.274
Chronic renal
insufficiency
1 (1%) 1 (3%) 0.447 0 (0%) 1 (5%) 0.999
 1 medicament
daily
26 (25%) 19 (53%) 0.003 4 (24%) 15 (79%) 0.001
 2 medicaments
daily
7 (7%) 13 (36%) <0.001 2 (12%) 11 (58%) 0.006
AST, U/l 25 ± 12 43 ± 26 <0.001 34 ± 25 50 ± 26 0.032
ALT, U/l 31 ± 37 43 ± 33 0.006 39 ± 29 46 ± 36 0.436
GGT, U/l 31 ± 31 100 ± 124 <0.001 38 ± 20 150 ± 150 <0.001
Alkaline
phosphatase, U/l
74 ± 34 87 ± 46 0.184 69 ± 27 102 ± 53 0.180
Bilirubin, μmol/l 9.2 ± 6 19 ± 17 0.003 8 ± 4 25 ± 17 0.001
Albumin 35 ± 7 34 ± 4 0.213 33 ± 4 35 ± 4 0.413
Quick, % 98 ± 4 81 ± 20 <0.001 93 ± 0.3 75 ± 20 0.021
Creatinine, μmol/l 80 ± 22 78 ± 20 0.746 91 ± 19 75 ± 21 0.153
Values are the mean ± SD or n. p-values were calculated using Mann-Whitney U or Fisher’s exact test, as appropriate.
MR = magnetic resonance; BMI = body mass index; AST = aspartate transaminase; ALT = alanine aminotransferase; GGT = gamma-glutamyltransferase
https://doi.org/10.1371/journal.pone.0199611.t001
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Clinical workup
Of the 141 patients who accepted the invitation for MR elastography, LIMVA-FS cutoff value
to predict significant liver fibrosis was positive in 17 patients. Fifteen of these 17 patients had
Table 2. Fibrosis scores and specific fibrosis risk factors of the MR elastography study population.
Normal liver
stiffness(n = 105)
Any degree of liver fibrosis
(shear modulus  2.8 kPa)
(n = 36)
p—
value
Beginning liver fibrosis(shear
modulus 2.8–3.5 kPa)(n = 17)
Significant liver fibrosis(shear
modulus 3.5 kPa)(n = 19)
p—
value
LIMVA-FS 25 ± 11 12 ± 9 <0.001 18 ± 9 6 ± 3 <0.001
LIMA-FS 1.2 ± 0.6 2.7 ± 1.4 <0.001 1.6 ± 0.8 3.7 ± 1.2 <0.001
LIMV-FS 30 ± 8 21 ± 6 <0.001 24 ± 5 18 ± 5 <0.001
CRL-R 0.85 ± 0.14 1.04 ± 0.20 <0.001 0.99 ± 0.21 1.08 ± 0.18 0.178
APRI 0.7 ± 1.4 1.2 ± 1.2 0.062 0.4 ± 0.3 1.9 ± 1.2 0.006
Hepatic proton
density fat fraction, %
9 ± 6 13 ± 10 0.009 13 ± 9 13 ± 11 0.917
Post-viral hepatitis
status
3 (3%) 11 (31%) <0.001 3 (18%) 8 (42%) 0.156
Chronic hepatitis B
or C
2 (2%) 7 (19%) 0.001 0 (0%) 7 (37%) 0.008
Ascites 2 (2%) 2 (6%) 0.269 0 (0%) 2 (11%) 0.487
Alcohol units per day 0.0 ± 0.3 0.8 ± 1.9 <0.001 0.4 ± 1.5 1.2 ± 2.2 0.007
Values are mean ± SD or n. p-values calculated using Mann-Whitney U or Fisher’s exact test, as appropriate.
MR = magnetic resonance; LIMVA-FS = liver imaging morphology, vein diameter and attenuation fibrosis score; LIMA-FS = liver imaging morphology and attenuation
fibrosis score, LIMV-FS = liver imaging morphology and vein diameter fibrosis score; CRL-R = caudate-right-lobe ratio; APRI = aspartate aminotransferase-to-platelet
ratio index
https://doi.org/10.1371/journal.pone.0199611.t002
Fig 4. Comparison of LVCA and liver stiffness. Mean liver stiffness as well as 95%-confidence interval are shown for
the different LVCA scores (1–4). Comparison between normal LVCA (1) and abnormal LVCA (2–4) was performed
using a Mann-Whitney-U test and p-values are indicated. LVCA was defined as liver vein attenuation 1 cm before the
confluent compared to inferior cava vein 1 cm before the confluent as follows: 1 hyper-attenuating, 2 iso-attenuating, 3
hypo-attenuating, while 4 indicates no contrast enhancement of liver veins. MR = magnetic resonance; LVCA = liver
vein to cava attenuation.
https://doi.org/10.1371/journal.pone.0199611.g004
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Fig 5. ROC analysis. ROC curves that separate patients with normal liver stiffness from patients with any degree of fibrosis (shear modulus2.8 kPa) are shown in the
left panel. ROC-curves of different CT fibrosis scores to predict clinically significant liver fibrosis (shear modulus3.5 kPa) are shown in the right panel.
CRL-R = caudate-right-lobe ratio; LIMA-FS = liver imaging morphology and attenuation fibrosis score; LIMV-FS = liver imaging morphology and vein diameter
fibrosis score; LIMVA-FS = liver imaging morphology, vein diameter and attenuation fibrosis score.
https://doi.org/10.1371/journal.pone.0199611.g005
Table 3. ROC analysis of liver imaging morphology-based fibrosis scores of the MR elastography study population (n = 141).
CRL-R LIMA LIMA LIMV LIMVA LIMVA
Cutoff value 0.98 1.96 2.85 20.0 11.7 6.7
Any degree of liver fibrosis
(>2.8 kPa, equivalent to F1-F4)
AUC 0.78 (0.68–0.88) 0.83 (0.75–0.92) 0.83 (0.75–0.92) 0.84 (0.76–0.91) 0.84 (0.76–0.91) 0.84 (0.76–0.92)
Youden’s index 57.1 55.0 43.5 41.6 55.0 40.7
Sensitivity 69% 67% 44% 44% 67% 42%
Specificity 88% 88% 99% 97% 88% 98.
Accuracy 83% 83% 85% 84% 83% 84%
PPV 57% (48–73%) 57% (49–73%) 92% (89–96%) 78% (72–88%) 57% (49–73%) 83% (78–91%)
NPV 93% (86–95%) 92% (94–100%) 88% (79–92%) 88% (79–91%) 92% (85–94%) 88% (78–91%)
Significant liver fibrosis
(>3.5 kPa, equivalent to F2-F4)
AUC 0.82 (0.70–0.94) 0.96 (0.91–1.00) 0.96 (0.91–1.00) 0.94 (0.88–0.99) 0.97 (0.93–1.00) 0.97 (0.93–1.00)
Youden’s index 60.1 75.5 77.3 75.7 79.7 78.1
Sensitivity 79% 89% 79% 79% 95% 79%
Specificity 81% 86% 98% 97% 85% 98%
Accuracy 81% 87% 95% 94% 86% 96%
PPV 29% (21–46%) 38% (29–57%) 76% (67–96%) 70% (59–83%) 41% (30–59%) 82% (74–91%)
NPV 97% (95–98%) 99% (99–100%) 98% (96–99%) 98% (96–99%) 100% (100%) 98% (96–99%)
The cutoff values are chosen based on Youden’s index. For LIMA and LIMVA, a second cutoff optimized for specificity is shown. PPV and NPV are corrected with the
estimated prevalence in the present study population. Estimated PPV and NPV are calculated based on the mean estimated prevalence, as well as the lowest and highest
estimated prevalence (shown in brackets).
ROC = receiver operating characteristics; CRL-R = caudate-right-lobe ratio; LIMA-FS = liver imaging morphology and attenuation fibrosis score, LIMV-FS = liver
imaging morphology and vein diameter fibrosis score; LIMVA-FS = liver imaging morphology, vein diameter and attenuation fibrosis score; AUC = area under the
receiver operating curve; PPV = positive predictive value; NPV = negative predictive value
https://doi.org/10.1371/journal.pone.0199611.t003
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liver fibrosis confirmed by MR elastography. Of note, MR elastography was in 100% accor-
dance with the clinical workup in all patients with significant liver fibrosis. 2 out of 17 patients
had a false-positive LIMVA-FS. Another 4 patients were positive for MR elastography with a
false-negative LIMVA-FS. From these 4 patients, one had an increased shear modulus of 4.1
kPa and significant liver fibrosis confirmed in the hepatological workup. The three others all
had borderline MR elastography values between 3.5–3.54 kPa with clearly elevated liver proton
density fat fractions between 32–39% indicating significant liver steatosis. One of these
patients underwent liver biopsy with fibrosis Metavir grade F1 and macrovesicular steatosis in
50% of the hepatocytes. Unfortunately, the two other patients did not show up for the hepato-
logical workup despite several invitations.
Interreader reliability
Interreader reliability was good for all the measured CT fibrosis scores. Two-way consistency
ICC was 0.72 for LIMA-FS, 0.72 for CRL-R, 0.65 for LIMV-FS and 0.66 for LIMVA-FS
between two independent, blinded readers (V.O. and A.H.).
Discussion
This study shows that CT-based quantitative scores allow prediction of significant liver fibro-
sis. Notably, enhancement of these scores with liver vein attenuation in portal venous phase
(LIMVA-FS and LIMA-FS), as a simplified surrogate for liver perfusion resulted in a better
performance than the purely morphology-based score CRL-R [20,21]. Although we performed
the easy to use LVCA on portal venous CT scans and did not use dynamic contrast enhanced
CT perfusion studies, this is in accordance with the results by Ronot et al. They have analyzed
reduced perfusion in liver fibrosis with CT [26]. Our results are also in agreement with the
underlying hypothesis of MR intravoxel incoherent motion (IVIM) [35]. Increased transfer
Table 4. Extrapolation of the ROC results of the MR elastography study population to 1534 consecutive CT scans.
CRL-R LIMA LIMA LIMV LIMVA LIMVA
Cutoff value 0.98 1.96 2.85 20.0 11.7 6.7
Any degree of liver fibrosis (>2.8 kPa, equivalent to F1-F4)
Estimated TP 209 147 116 219 160 90
Estimated TN 1080 1161 1261 1011 1143 1291
Estimated FP 153 153 12 30 151 26
Estimated FN 92 73 145 274 80 127
Estimated prevalence 20% 15% 17% 32% 16% 14%
Mean estimated prevalence 19 ± 7%
Significant liver fibrosis (>3.5 kPa, equivalent to F2-F4)
Estimated TP 96 83 93 207 109 92
Estimated TN 1146 1229 1381 1230 1223 1393
Estimated FP 266 217 35 42 202 24
Estimated FN 26 5 25 55 0 25
Estimated prevalence 8% 6% 8% 17% 7% 8%
Mean estimated prevalence 9 ± 4%
Values are n or %. Mean prevalence is shown ± standard deviation.
MR = magnetic resonance; ROC = receiver operating characteristics; CRL-R = caudate-right-lobe ratio; LIMA-FS = liver imaging morphology and attenuation fibrosis
score, LIMV-FS = liver imaging morphology and vein diameter fibrosis score; LIMVA-FS = liver imaging morphology, vein diameter and attenuation fibrosis score;
TP = true positives; TN = true negatives; FP = false positives; FN = false negatives; PPV = positive predictive value; NPV = negative predictive value
https://doi.org/10.1371/journal.pone.0199611.t004
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transit time of low-molecular-weight compounds such as contrast agents might be explained
by an increasing number of stellate cells, a loss of fenestrae of the sinusoids and the deposition
of collagen fibers in the space of Disse in liver fibrosis [36].
All four presented fibrosis scores have the great advantage to allow retrospective calculation
on any portal venous abdominal CT scan on axial planes without time-consuming post-pro-
cessing. Compared with visual analysis on CT scans by experienced radiologists [16], they
have all the advantages of quantitative scores that are easily measurable and reproducible.
LIMVA-FS and LIMA-FS, combining morphology and a simplified surrogate for perfusion,
showed better performances than pure perfusion studies, such as the MR perfusion study of Hagi-
wara et al., who reported an AUC of 0.84 to detect fibrosisF3 [27]. If just CRL-R without perfu-
sion was analyzed, the resulting AUC of 0.82 was only slightly lower than the AUC of 0.86
achieved by Pickhardt et al. with more time-consuming caudate to right lobe volumetry [17]. This
difference might be explained by the higher accuracy of volumetry relative to the two-dimensional
CRL-R calculation but also by the fact that Pickardt et al. used a cutoff valueF3, representing a
more advanced fibrosis grade than the cutoff value for significant fibrosis we used in this study.
However, if CRL-R was extended by the simplified perfusion metric, we showed a higher AUC of
0.96–0.97 to predict significant liver remodeling using LIMA-FS and LIMVA-FS.
Fig 6. Scatterplots of MR elastography compared with LIMV-FS and CRL-R and their attenuation based complements LIMVA-FS and LIMA-FS. Dashed lines
indicate the calculated cutoff values from the ROC analysis on the y-axis and MR elastography cutoff values for early and significant liver fibrosis on the x-axis. On the
right side of each figure, 20 consecutive patients with abdominal CT scans and known biopsy-confirmed liver cirrhosis (Metavir score F4) are shown. These patients are
shown as positive controls but not included in any statistical analysis. The Pearson correlation r value is shown on every figure, using 1/LIMV-FS and 1/LIMVA-FS due
to the inverse correlation with MR elastography. MR = magnetic resonance; LIMV-FS = liver imaging morphology and vein diameter fibrosis score; LIMVA-FS = liver
imaging morphology, vein diameter and attenuation fibrosis score; CRL-R = caudate-right-lobe ratio; LIMA-FS = liver imaging morphology and attenuation fibrosis
score; ROC = receiver operating characteristics.
https://doi.org/10.1371/journal.pone.0199611.g006
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Our CT based prevalence estimation of 9% for significant liver remodeling is very compara-
ble to the prevalence of significant fibrosis at 7.5% in the general population using FibroScan1
in cross-sectional studies [12]. The prevalence estimation allowed us to calculate PPV and
NPV, thus showing that patients with a LIMVA-FS6.7 could be referred to a hepatology
department with a PPV of 82% for significant liver remodeling while NPV for patients with
LIMVA-FS above this cutoff would be 98%.
Despite the existence of FibroScan1 as a cheap, accurate and reliable non-invasive method
to stage liver fibrosis, chronic liver disease is frequent [37] and under recognized [5,6]. Because
of the ubiquity of CT in clinical practice, extractions of all possible information from abdomi-
nal CT scans are compulsory. For this purpose, LIMVA-FS and LIMA-FS are useful non-inva-
sive imaging biomarkers. Patients with unknown liver disease could be depicted and referred
to a hepatology department for further workup. Early detection of these patients might allow
personalized treatments during reversible fibrosis stages, before irreversible cirrhosis occurs
[7], and as a primary prevention of HCC.
Based on our results, we propose a possible clinical workflow, as shown in Fig 7. Since
LIMA-FS is calculated more quickly than LIMVA-FS, we propose to screen every abdominal
CT scan in the portal venous phase with an excellent NPV if LIMA-FS <2.85. This score can
be calculated in less than 1 minute on axial CT stacks. In cases of LIMA-FS2.85, we propose
to calculate LIMVA-FS with a PPV of 82% for significant liver remodeling if LIMVA-FS <6.7.
In the rare case of a positive LIMA-FS and a negative LIMVA-FS, we recommend a stratifica-
tion of the hepatic risk factors and consideration of the special case of chronic hepatic conges-
tion due to heart failure, which might present as liver fibrosis with dilated liver veins. In those
cases variation of liver veins and IVC enhancement as result of cardiac output and injection
properties might influence LIMA-FS and LIMVA-FS.
Our study has several limitations. Due to the ethical considerations, we used MR elastogra-
phy as the non-invasive gold standard and not liver biopsy to assess liver fibrosis. This allowed
us to investigate a general patient population without known chronic liver disease. MR elasto-
graphy has shown excellent accuracy with biopsy-confirmed fibrosis grades [38,39]. Another
possible limitation is that moderately increased liver stiffness may also be caused by hepatic
Fig 7. Possible clinical workflow based on LIMA-FS and LIMVA-FS in portal venous abdominal CT scans.
CT = computed tomography; LIMA-FS = liver imaging morphology and attenuation fibrosis score; LIMVA-FS = liver
imaging morphology, vein diameter and attenuation fibrosis score; NPV = negative predictive value; PPV = positive
predictive value.
https://doi.org/10.1371/journal.pone.0199611.g007
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inflammation, steatosis or ingestion of a fatty meal [32]. To mitigate these possible biases, all
patients underwent MR elastography in the fasting state, and the hepatic proton density fat
fractions were measured, without differences in the hepatic proton density fat fraction between
patients with beginning and significant liver remodeling. Another limitation of LIMA-FS and
LIMVA-FS involves the normal variants of portal vein anatomy, which are not infrequent. To
address this possible drawback, we introduced a definition for the measurement in case of por-
tal venous variants, and interrater reliability was good for all presented CT scores. Last but not
least, LVCA may be affected by several confounding factors such as different CT manufactur-
ers and contrast media types and injected flow rates. In addition, LVCA is not a real perfusion
parameter since we did not evaluate dynamic contrast enhanced CT perfusion studies but cate-
gorized LVCA based on Hounsfield Units in portal venous scans. However, simplified LVCA
has the advantage being applicable on any portal venous CT scan of the abdomen without
applying higher radiation dose to the patient as it is the case in CT perfusion studies.
In conclusion, notably LIMA-FS and LIMVA-FS, allow to predict significant liver fibrosis
with high PPV on routine CT scans. These simple quantifiable metrics are highly reproducible
and may be retrospectively calculated on axial planes without time-consuming post-process-
ing. Patients with unknown liver fibrosis may be referred to a hepatology department for spe-
cific workup and adequate treatment as a primary prevention of liver cirrhosis, liver failure
and HCC.
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